Updated: May 12
SGS Colombia SAS, in Collaboration with Ikänik, Seeks To Enhance and Harmonize International Medicinal Cannabis Production Standards
CORONA, CA, Oct. 29, 2019 /CNW/ - Ikänik Farms (the "Company") is pleased to announce that Ikänik International, Inc., a wholly owned subsidiary of Ikänik Farms, Inc. ("Ikänik"), has signed a 6-month cooperative agreement with SGS Colombia SAS ("SGS") to design, initiate, develop and implement a normative document for the international certification of medicinal cannabis, which is currently in the development stage. This document is intended to establish a new standard for the quality and safety of pharmaceutical grade cannabis products (GMP-C).
"Ikänik aims to be the first multinational cannabis operator in the world to have a large-scale GMP-C certified cannabis production complex," said Brian Baca, CEO of Ikänik Farms, Inc. "We look forward to working alongside SGS Colombia SAS to develop what we believe could become the world's preeminent benchmark for medicinal cannabis production."
Whereas traditional pharmaceutical GMP standards require a single transformation laboratory to be GMP certified, the GMP-C model as set forth by SGS requires cannabis companies to obtain GMP certification for each stage in the cannabis production process (i.e. cultivation, extraction, manufacturing) through having all processes standardized. By applying the GMP standard across numerous cannabis production and manufacturing processes, GMP-C has the potential to reduce the risk of cross-contamination while ensuring that cannabis materials comply with the industry's highest aseptic and disinfection standards.
GMP-C Certification Process
The first step for Ikänik, with the assistance of SGS, will be to finish the regulatory document that will determine the conditions for medical cannabis production. Over the following 15 days, meetings with SGS and Ikänik representatives will be held to determine the work plan and to define the requirements that must be fulfilled to achieve GMP-C certification. Following completion of the regulatory document, SGS, in collaboration with Ikänik, will have the technical, scientific and standardized processes necessary to support international (Europe and North America) medical cannabis production standards for GMP-C. Once the standard is assessed and reviewed by specialized committees from SGS, the GMP-C certification will be established. SGS will then publish a final standardization report.
Ikänik aims to have the GMP-C certification model complete in Q1 2020.
About SGS Colombia SAS
SGS Colombia SAS is a subsidiary of SGS SA, the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.
About Ikänik Farms
Ikänik Farms is creating a dynamic portfolio of award-winning cannabis lifestyle brands, deep rooted in action sports and entertainment and unified with passion. Ikänik's leadership brings decades of expertise in R&D, cultivation, retail, branding, and corporate finance with the ambition to build the nation's most iconic vertically integrated "seed-to-sale", "MNO" Multi-National Operator. Ikänik's operations are currently located in California and Colombia.
Forward Looking Statements
This news release includes "forward-looking information" and "forward-looking statements" within the meaning of Canadian securities laws and United States securities laws (together, "forward-looking information). All information, other than statements of historical facts, included in this news release that address activities, events or developments that the Company expects or anticipates will or may occur in the future is forward-looking information. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "believe", "should", and similar expressions, are forward-looking information, including, but not limited to, Ikanik being the first multinational cannabis operator in the world to have a large-scale GMP-C certified cannabis production complex, Ikanik's ability to obtain GMP or GMP-C certification and the GMP-C certification process.
Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: Ikanik not being able to obtain GMP or GMP-C certification for any reason, there being material amendments to, or termination of, the agreement with SGS.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in the forward-looking information may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information in this news release is made as of the date of this release. The Company disclaims any intention or obligation to update or revise such information, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.
SOURCE Ikänik Farms Inc.
For further information: Bill Keating, Chief Operating Officer, bkeating@Ikänikfarms.com, (905) 330-5002; Brian Baca Chief Executive Officer, bbaca@Ikänikfarms.com, (775) 843-1051